Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease

Circulation

Volumn 99, Issue 5, 1999, Pages 614-619

  Kiechl, Stefan ^a   Muigg, Armin ^a   Santer, Peter ^b   Mitterer, Manfred ^c   Egger, Georg ^b   Oberhollenzer, Martin ^b   Oberhollenzer, Friedrich ^b   Mayr, Agnes ^b   Gasperi, Arno ^b   Poewe, Werner ^a   Willeit, Johann ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b BRUNECK HOSPITAL   (Italy)

^c Bozen Hospital   (Italy)

Author keywords

Arteries; Atherosclerosis; Cardiovascular diseases; Proteins; Thrombosis; Ultrasonics

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY THROMBOSIS; DISEASE ASSOCIATION; FEMALE; FEMORAL ARTERY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; ULTRASOUND;

EID: 0033537469     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.5.614     Document Type: Article

References (31)

1. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb. 1992;12:135-145.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
3. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
4. De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost. 1994;72:880-886.
5. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94: 2521-2524.
6. Fisher M, Fernández JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine 506-glutamine mutation. Stroke. 1996;27:1163-1166.
7. Dahlbäck B. Physiological anticoagulation: resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994;94:923-927.
8. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
9. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II):II-3-II-16.
10. Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis: a population-based study. Arterioscler Thromb. 1993;13:661-668.
11. Feigelson HS, Criqui MH, Fronek A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140:526-534.
12. Rose G, Blackburn H, Gillum R. Cardiovascular Survey Methods. Geneva, Switzerland: WHO; 1982.
13. IHD Register. Report of the Fifth Working Group. Copenhagen, Denmark: WHO, Regional Office for Europe; 1971.
14. Walker A, Robins M, Weinfeld F. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl I):I-13-I-49.
15. Rosen S, Johansson K, Lindberg K, Dahlbäck B, and the APC-Resistance Study Group. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost. 1994;72:255-260.
16. Van den Besselaar AM, Meeuwisse-Braun J. Enzymatic elimination of heparin from plasma for activated partial thromboplastin time and prothrombin time testing. Blood Coagul Fibrinolysis. 1993;4:635-638.
17. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981;57:199-202.
18. Blasczyk R, Ritter M, Thiede C, Wehling J, Hintz G, Neubauer A, Riess H. Simple and rapid detection of factor V Leiden by allele-specific PCR amplification. Thromb Haemost. 1996;75:757-759.
19. Lilliefors HW. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. J Am Stat Assoc. 1967;62:399-402.
20. Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc. 1977;72:46-53.
21. Hosmer D, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1988.
22. Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost. 1991;66:49-61.
23. Van der Bom JG, Bots ML, Haverkate F, Slagboom E, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
24. Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost. 1995;73:402-404.
25. Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994;5:51-57.
26. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke. 1995; 26:885-890.
27. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg. 1996;23:46-51.
28. 506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558-560.
29. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
30. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783-785.
31. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996;27:44-48.